These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38445541)

  • 1. The myeloperoxidase inhibitor mitiperstat (AZD4831) does not prolong the QT interval at expected therapeutic doses.
    Parkinson J; Sundell J; Rekić D; Nelander K; Ericsson H; Ebrahimi A; Dota C; Sunnåker M
    Pharmacol Res Perspect; 2024 Apr; 12(2):e1184. PubMed ID: 38445541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT.
    Henrich A; Juif PE; Dingemanse J; Krause A
    J Pharmacokinet Pharmacodyn; 2021 Apr; 48(2):213-224. PubMed ID: 33389549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes.
    Böttcher M; Düngen HD; Corcea V; Donath F; Fuhr R; Gal P; Mikus G; Trenk D; Coenen M; Pires PV; Maschke C; Aliprantis AO; Besche N; Becker C
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):145-155. PubMed ID: 36633816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentration-QT modelling shows no evidence of clinically significant QT interval prolongation with capivasertib at expected therapeutic concentrations.
    Voronova V; Cullberg M; Delff P; Parkinson J; Dota C; Schiavon G; Maroj B; Rekić D; Cheung SYA
    Br J Clin Pharmacol; 2022 Feb; 88(2):858-864. PubMed ID: 34309049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors.
    Quinlan M; Zhou J; Hurh E; Sellami D
    Eur J Clin Pharmacol; 2016 Dec; 72(12):1427-1432. PubMed ID: 27663457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloperoxidase Inhibition in Heart Failure With Preserved or Mildly Reduced Ejection Fraction: SATELLITE Trial Results.
    Lam CSP; Lund LH; Shah SJ; Voors AA; Erlinge D; Saraste A; Pirazzi C; Grove EL; Barasa A; Schou M; Aziz A; Svedlund S; Wijngaarden JV; Lindstedt EL; Gustavsson A; Nelander K; Garkaviy P; Gan LM; Gabrielsen A
    J Card Fail; 2024 Jan; 30(1):104-110. PubMed ID: 37072105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
    He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
    Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of QT Prolongation for 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects.
    Yu RZ; Gunawan R; Geary RS; Hughes SG; Henry SP; Wang Y
    Nucleic Acid Ther; 2017 Oct; 27(5):285-294. PubMed ID: 28799823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
    Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
    Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous Amisulpride Does Not Meaningfully Prolong the QTc Interval at Doses Effective for the Management of Postoperative Nausea and Vomiting.
    Fox GM; Albayaty M; Walker JL; Xue H; Darpo B
    Anesth Analg; 2021 Jan; 132(1):150-159. PubMed ID: 31913911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 1, double-blind, 4-period crossover study to investigate the effects of pomalidomide on QT interval in healthy male subjects.
    Mondal SA; Assaf M; Liu L; O'Mara E
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):251-8. PubMed ID: 26754679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
    Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
    Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers.
    Hossain M; Zhou M; Tiffany C; Dumont E; Darpo B
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verinurad does not prolong QTc interval: a thorough QT study using concentration-QTc modelling.
    Parkinson J; Dota C; Källgren C; Gottfridsson C; Bjursell M; Perl S; Kӧrnicke T; Rekić D; Johansson S
    Br J Clin Pharmacol; 2023 Jun; 89(6):1747-1755. PubMed ID: 36504291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Approach to Evaluating QT Prolongation of Quetiapine Fumarate in Late Stage of Clinical Development Using Concentration-QTc Modeling and Simulation in Japanese Patients With Bipolar Disorder.
    Fukushi R; Nomura Y; Katashima M; Komatsu K; Sato Y; Takada A
    Clin Ther; 2020 Aug; 42(8):1483-1493.e1. PubMed ID: 32792252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval.
    Rekić D; Azarov I; Knöchel J; Sokolov V; Nilsson C; Wernevik L; Han D; Rydén-Bergsten T; Ebrahimi A; Dota C; Carlsson B
    Br J Clin Pharmacol; 2022 Nov; 88(11):4839-4844. PubMed ID: 35653229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.